NRIX · NASDAQ
Nurix Therapeutics (NRIX) Stock Price & Fundamentals
Nurix Therapeutics (NRIX) closed at $982.25 on Oct 9, 2026, up 0.94% from the previous close of $973.06.
Share price, past year
1Y +12.68%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $982.25 |
| Sep 30, 2026 | $981.15 |
| Aug 31, 2026 | $973.46 |
| Jul 31, 2026 | $955.82 |
| Jun 30, 2026 | $979.45 |
| May 29, 2026 | $1,000.52 |
| Apr 30, 2026 | $1,027.73 |
| Mar 31, 2026 | $976.66 |
| Feb 27, 2026 | $993.15 |
| Jan 30, 2026 | $897.18 |
| Dec 31, 2025 | $878.66 |
| Nov 28, 2025 | $857.83 |
| Oct 31, 2025 | $888.50 |
Key statistics
- Market cap
- $101.86B
- P/E (TTM)
- —
- EPS (TTM)
- −$3.46
- Revenue (TTM)
- $36.77M
- Net income (TTM)
- −$341.35M
- Shares outstanding
- 103.7M
- Dividend yield
- —
- 52-week range
- $847.91 – $1,047.65
Nurix Therapeutics's market cap is $101.86B, based on a share price of $982.25 and 103.7M shares outstanding as of May 31, 2026.
Financials
Nurix Therapeutics reported revenue of $83.98M for fiscal 2025, up 53.95% from fiscal 2024.
Nurix Therapeutics reported a net loss of $264.46M in fiscal 2025.
Fiscal 2025 revenue was the highest in the 7 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Nov 30, 2025 | $83.98M | +54.0% | −$264.46M | −314.9% | −$3.05 | −$263.47M |
| FY2024ended Nov 30, 2024 | $54.55M | −29.2% | −$193.57M | −354.9% | −$2.88 | −$181.86M |
| FY2023ended Nov 30, 2023 | $76.99M | +99.3% | −$143.95M | −187.0% | −$2.65 | −$89.77M |
| FY2022ended Nov 30, 2022 | $38.63M | +29.8% | −$180.36M | −466.9% | −$3.71 | −$172.05M |
| FY2021ended Nov 30, 2021 | $29.75M | +67.0% | −$117.19M | −393.9% | −$2.73 | −$90.03M |
| FY2020ended Nov 30, 2020 | $17.82M | −42.7% | −$43.24M | −242.7% | −$2.76 | −$4.63M |
| FY2019ended Nov 30, 2019 | $31.12M | — | −$21.70M | −69.7% | −$6.59 | −$1.05M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended May 31, 2026 | $9.04M | −$89.54M | −$0.81 |
| Q1 FY2026ended Feb 28, 2026 | $6.25M | −$87.17M | −$0.79 |
| Q4 FY2025ended Nov 30, 2025 | $13.58M | −$78.22M | −$0.83 |
| Q3 FY2025ended Aug 31, 2025 | $7.89M | −$86.42M | −$1.03 |
| Q2 FY2025ended May 31, 2025 | $44.06M | −$43.46M | −$0.52 |
| Q1 FY2025ended Feb 28, 2025 | $18.45M | −$56.35M | −$0.67 |
| Q4 FY2024ended Nov 30, 2024 | $13.28M | −$58.55M | −$0.74 |
| Q3 FY2024ended Aug 31, 2024 | $12.59M | −$48.96M | −$0.67 |
Company profile
- Name
- Nurix Therapeutics, Inc.
- Ticker
- NRIX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 1600 Sierra Point Pkwy, Brisbane, CA 94005
- Incorporated in
- DE
- Fiscal year ends
- November
- SEC CIK
- 0001549595
Recent SEC filings
- Jul 9, 2026
- Jul 9, 2026
- Jun 11, 2026
- Jun 8, 2026
- May 15, 2026
- Apr 8, 2026
- Apr 8, 2026
- Mar 6, 2026
Frequently asked questions
What is Nurix Therapeutics's stock price?
Nurix Therapeutics (NRIX) closed at $982.25 on Oct 9, 2026, up 0.94% from the previous close of $973.06.
What is Nurix Therapeutics's market cap?
Nurix Therapeutics's market cap is $101.86B, based on a share price of $982.25 and 103.7M shares outstanding as of May 31, 2026.
How much revenue does Nurix Therapeutics make?
Nurix Therapeutics reported revenue of $83.98M for fiscal 2025, up 53.95% from fiscal 2024.
Does Nurix Therapeutics pay a dividend?
Yes. Nurix Therapeutics declared $0.00 per share in dividends for fiscal 2025.
Sources and methodology
Fundamentals come from Nurix Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures